Quantum BioPharma Completes Oral Dosing Studies for Lucid-MS, Advancing IND Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy QNTM?
Source: Globenewswire
- Research Progress: Quantum BioPharma has completed the 180-day toxicity and toxicokinetic studies for Lucid-MS, laying the groundwork for the Investigational New Drug (IND) application to the US FDA, which will expedite the initiation of Phase 2 clinical trials for multiple sclerosis (MS).
- Clinical Potential: With the completion of toxicity studies, Quantum BioPharma has taken two significant steps forward, indicating that Lucid-MS, as a first-in-class treatment, has the potential to prevent disease progression and inhibit demyelination, showcasing its substantial clinical application potential.
- Strategic Investment: Through its wholly-owned subsidiary, Lucid Psycheceuticals, Quantum BioPharma focuses on the R&D of Lucid-MS, demonstrating the company's long-term commitment to treating neurodegenerative diseases and aiming to meet the growing market demand.
- Market Outlook: As demand for novel treatment options increases, Quantum BioPharma's research outcomes could potentially yield significant market share and revenue growth in the future, further solidifying its position in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades that artificially deflated the price of Quantum Biopharma Ltd. (NASDAQ: QNTM) stock.
- Manipulative Trading Practices: The complaint alleges that throughout the class period, the defendants repeatedly placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially depressed prices, allowing the defendants to profit from the scheme.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their Quantum shares at lower than market value, with the lawsuit seeking damages on behalf of all individuals who sold Quantum securities between January 6, 2021, and October 15, 2025.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful in recovering losses, allowing investors to participate in the lawsuit without financial risk.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell Quantum shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover losses, thereby minimizing financial risk for investors.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which misled investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds, thereby minimizing the financial risk for investors.
See More
Quantum Biopharma Ltd. Class Action Notice for Investors
- Class Action Notice: Quantum Biopharma Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Trading Allegations: The lawsuit alleges that the company engaged in thousands of spoofed sell orders during the class period, intentionally creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, highlighting severe governance issues within the company.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at artificially low prices, resulting in undue losses, which suggests potential misconduct in market manipulation that could lead to broader legal repercussions.
- Legal Consultation Opportunity: Investors can obtain a complimentary case evaluation from the Portnoy Law Firm, indicating that the firm is actively providing legal support for affected investors, which may influence future investor confidence and market performance.
See More
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and further depress stock prices.
- Manipulative Trading Allegations: The complaint accuses financial institutions like CIBC and RBC of placing thousands of spoofed sell orders to create a false impression of declining stock prices, leading other investors to sell at artificially low prices and incurring significant losses.
- Investor Rights Protection: Shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting their strong concerns regarding corporate governance and transparency.
- Law Firm Credentials: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
See More
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and lead to further stock price declines.
- False Trading Allegations: The lawsuit claims that financial institutions like CIBC and RBC executed thousands of spoofed sell orders to create a false impression of Quantum's stock price decline, misleading other investors into selling their shares at artificially low prices, thereby harming investor interests.
- Investor Action Deadline: Affected Quantum shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact of this case on shareholder rights and its significance.
- Law Firm Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades that artificially deflated the price of Quantum Biopharma Ltd. (NASDAQ: QNTM) stock.
- Manipulative Trading Practices: The complaint alleges that throughout the class period, the defendants repeatedly placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially depressed prices, allowing the defendants to profit from the scheme.
- Investor Losses: As a result of the defendants' misconduct, investors were improperly induced to sell their Quantum shares at lower than market value, with the lawsuit seeking damages on behalf of all individuals who sold Quantum securities between January 6, 2021, and October 15, 2025.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees from the court if they are successful in recovering losses, allowing investors to participate in the lawsuit without financial risk.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which deceived investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell Quantum shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- No Cost for Investors: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover losses, thereby minimizing financial risk for investors.
See More
CIBC and RBC Accused of Manipulating Quantum Stock Prices
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC), alleging that they defrauded investors by manipulating trades to artificially depress the stock price of Quantum Biopharma Ltd. (NASDAQ: QNTM).
- Manipulative Trading Allegations: The complaint claims that from January 6, 2021, to October 15, 2025, the defendants placed thousands of spoofed sell orders, creating a false impression of declining stock prices, which misled investors into selling their shares at artificially low prices.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at depressed prices, and the lawsuit seeks to recover damages for all individuals who sold Quantum securities during the class period.
- Contingency Fee Arrangement: Bronstein, Gewirtz & Grossman LLC represents investors on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if they successfully recover funds, thereby minimizing the financial risk for investors.
See More
Quantum Biopharma Ltd. Class Action Notice for Investors
- Class Action Notice: Quantum Biopharma Ltd. is facing a class action lawsuit for securities transactions between January 6, 2021, and October 15, 2025, with investors required to file a lead plaintiff motion by February 23, 2026, indicating significant legal risks that may undermine shareholder confidence.
- False Trading Allegations: The lawsuit alleges that the company engaged in thousands of spoofed sell orders during the class period, intentionally creating a false appearance of declining stock prices, which led investors to sell their shares at artificially depressed prices, highlighting severe governance issues within the company.
- Investor Losses: As a result of the defendants' actions, investors were improperly induced to sell their shares at artificially low prices, resulting in undue losses, which suggests potential misconduct in market manipulation that could lead to broader legal repercussions.
- Legal Consultation Opportunity: Investors can obtain a complimentary case evaluation from the Portnoy Law Firm, indicating that the firm is actively providing legal support for affected investors, which may influence future investor confidence and market performance.
See More
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and further depress stock prices.
- Manipulative Trading Allegations: The complaint accuses financial institutions like CIBC and RBC of placing thousands of spoofed sell orders to create a false impression of declining stock prices, leading other investors to sell at artificially low prices and incurring significant losses.
- Investor Rights Protection: Shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting their strong concerns regarding corporate governance and transparency.
- Law Firm Credentials: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
See More
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and lead to further stock price declines.
- False Trading Allegations: The lawsuit claims that financial institutions like CIBC and RBC executed thousands of spoofed sell orders to create a false impression of Quantum's stock price decline, misleading other investors into selling their shares at artificially low prices, thereby harming investor interests.
- Investor Action Deadline: Affected Quantum shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact of this case on shareholder rights and its significance.
- Law Firm Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
See More
